State of the art in CAR T cell therapy for CD19+ B cell malignancies
| Autor: | Marcela V. Maus, Matthew J. Frigault |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Lymphoma B-Cell medicine.medical_treatment T cell Antigens CD19 Immunotherapy Adoptive CD19 Cell therapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans B cell B-Lymphocytes Receptors Chimeric Antigen biology business.industry Review Series General Medicine Immunotherapy medicine.disease Chimeric antigen receptor Lymphoma Clinical trial 030104 developmental biology medicine.anatomical_structure Hematologic Neoplasms 030220 oncology & carcinogenesis biology.protein business |
| Zdroj: | J Clin Invest |
| ISSN: | 1558-8238 0021-9738 |
| Popis: | Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell malignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the approval of this therapy by the FDA and the European Medicines Agency for specific indications. Despite strikingly similar efficacy, investigators at multiple centers participating in these studies have observed the nuances of each CAR T cell product, including variability in manufacturing, availability, and toxicity profiles. Here we review state-of-the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding and modeling associated toxicities, and several exciting advances and creative solutions for overcoming challenges with this therapeutic modality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|